HC Wainwright Predicts Kairos Pharma FY2026 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of Kairos Pharma in a note issued to investors on Thursday, April 2nd. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.38) per share for the year. HC Wainwright also issued estimates for Kairos Pharma’s FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.73) EPS.

Kairos Pharma (NYSEAMERICAN:KAPA) last released its earnings results on Tuesday, March 31st. The company reported ($0.07) earnings per share for the quarter.

Kairos Pharma Stock Down 4.5%

KAPA stock traded down $0.03 during trading on Tuesday, hitting $0.59. The company had a trading volume of 14,089 shares, compared to its average volume of 503,030. Kairos Pharma has a 52-week low of $0.40 and a 52-week high of $2.11. The company has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.82. The firm has a market capitalization of $12.67 million, a P/E ratio of -1.97 and a beta of 1.97.

Hedge Funds Weigh In On Kairos Pharma

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of Kairos Pharma during the second quarter valued at approximately $44,000. Two Sigma Investments LP bought a new position in Kairos Pharma in the third quarter worth approximately $54,000. Finally, FNY Investment Advisers LLC purchased a new position in Kairos Pharma during the 3rd quarter worth $27,000.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.